Assignee
DAEWOONG PHARMACEUTICAL CO LTD
KR·15 granted patents·31 pending applications·4 citations·filing 2018–2025
Top patents by PatentIndex Score
46 records- 0192US11459297B2Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine saltDAEWOONG PHARMACEUTICAL CO LTD·Filed 2021·Granted Oct 4, 2022·2 cites·4 claims
- 0282US2026078109A1Method for preparing sglt inhibitorDAEWOONG PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0382US2026085065A1Crystalline form of sglt inhibitorDAEWOONG PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0480US11858894B2Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine saltDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Granted Jan 2, 2024·0 cites·4 claims
- 0578US12303507B2Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemiaDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Granted May 20, 2025·1 cites·11 claims
- 0676US2026076874A1Two-chamber type combined container-syringeDAEWOONG PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0772US12227498B2Heterocyclic amine derivative and pharmaceutical composition comprising sameDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 18, 2025·1 cites·18 claims
- 0866US2026078411A1Novel genomic safe harbor and use thereofDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0965US12497390B2Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using sameDAEWOONG PHARMACEUTICAL CO LTD·Filed 2021·Granted Dec 16, 2025·0 cites·4 claims
- 1064US2022259146A1Method for preparing intermediate of 4-methoxypyrrole derivativeDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1163US2025074889A1Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active IngredientDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1263US2025051302A1Method for Preparation of (2R,3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol DerivativesDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1361US2025320233A1Arginase inhibitor and pharmaceutical composition comprising the sameDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1461US2025066319A1NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OLDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1560US2025268862A1Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditionsDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1658US2026098033A1Novel crystalline form of enavogliflozin, and preparation method thereforDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1758US2026022112A1Novel co-crystal of enavogliflozinDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1858US2024307365A1Pharmaceutical Composition for Preventing or Treating Systemic SclerosisDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1957US2025000839A1Pharmaceutical composition comprising enavogliflozinDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2057US2025092004A1Method for producing intermediate useful for synethesis of sglt inhibitorDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2156US2024216363A1Pharmaceutical composition for preventing or treating fibrosisDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2255US12447110B2Two-chamber type combined container-syringeDAEWOONG PHARMACEUTICAL CO LTD·Filed 2018·Granted Oct 21, 2025·0 cites·6 claims
- 2355US2024238278A1Pharmaceutical Composition for Preventing or Treating FibrosisDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2455US2025152555A1Pharmaceutical Composition for Preventing or Treating Triple-Negative Breast CancerDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2554US2026097060A1Pharmaceutical composition comprising enavogliflozin for preventing or treating cardiovascular aging diseasesDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2653US2023321046A1Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemiaDAEWOONG PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2753US2024415808A1Dosage Regimen for Fexuprazan Injection CompositionDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2852US2025073205A1Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamineDAEWOONG PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2952US2024245641A1Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozinDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3052US2025114387A1Pharmaceutical composition comprising enavogliflozin for preventing or treating obesity in canine animalsDAEWOONG PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3151US11407754B2Substituted piperidines as kinase inhibitorsDAEWOONG PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 9, 2022·0 cites·13 claims
- 3250US2023014770A1Method for preparation of mesenchymal stem cell from human pluripotent stem cell and mesenchymal stem cells prepared therebyDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3350US2023094404A1Method for preparation of heterocyclicamine derivativesDAEWOONG PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3449US2022389010A1Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising SameDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3546US12570991B2Recombinant yeast strain having sterol productivity, preparation method therefor and use thereofDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Mar 10, 2026·0 cites·2 claims
- 3646US11661406B2Method for producing intermediate useful for synthesis of SGLT inhibitorDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted May 30, 2023·0 cites·17 claims
- 3746US2024269070A1Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamineDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3845US11857773B2Syringe safety cap and safety syringe including the sameDAEWOONG PHARMACEUTICAL CO LTD·Filed 2018·Granted Jan 2, 2024·0 cites·17 claims
- 3945US2022226296A1Preparation for percutaneous absorption comprising high dose of donepezil or salt thereofDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4045US2024261261A1New formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamineDAEWOONG PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4144US11566059B2Long-acting insulin analogues and derivatives thereofDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Jan 31, 2023·0 cites·20 claims
- 4242US12110271B2Manufacturing method for 4-methoxypyrrole derivativesDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Oct 8, 2024·0 cites·22 claims
- 4341US2022387476A1Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamineDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4438US12448360B2Synthesis method for preparing SGLT inhibitor intermediateDAEWOONG PHARMACEUTICAL CO LTD·Filed 2020·Granted Oct 21, 2025·0 cites·11 claims
- 4537US11655279B2Method for producing active form of long-acting insulin analogue derivative using clostripainDAEWOONG PHARMACEUTICAL CO LTD·Filed 2019·Granted May 23, 2023·0 cites·18 claims
- 4636US11433054B2Pharmaceutical preparation and preparation method thereforDAEWOONG PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 6, 2022·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when DAEWOONG PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →